Initiating a 'Strong Buy' rating for CME with a fair value of $301 per share due to increased demand for hedging amid economic uncertainty and market volatility. CME's diverse product offerings and strong trading volume growth, particularly in interest rate options/futures, equity, FX, energy, and commodities, support its robust business model. CME's high operating margin, capex-light business model, and strategic use of Google Cloud enhance profitability and operational efficiency.

It's been a tough year for Tesla (TSLA 9.74%), shares of which are down by about 30% year to date and more than 40% below the peak they reached in December. Yet on paper, the stock still doesn't look like a screaming buy.

I upgrade lululemon to a "buy" as the company sees stabilization in the US market while sustaining momentum in its international markets through robust product innovation and superior guest experience. Despite a 32% stock decline since my last writing, lululemon's Q4 earnings beat estimates, showing strong revenue growth and margin expansion, particularly in international markets. While Tariff-related headwinds and rising inventory pose risks, with the management predicting a slowdown in FY25, easing trade tensions could offer potential upside.

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced patient-reported outcomes following treatment of patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) that showed investigational drug UGN-102 (mitomycin) for intravesical solution achieved robust and durable complete response (CR) rates without ne.

NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Perpetua Resources Corp. (NASDAQ: PPTA) between April 17, 2024 and February 13, 2025, both dates inclusive (the “Class Period”), of the important May 20, 2025 lead plaintiff deadline.

Blackstone Mortgage Trust: Various Dislocations Might Materialize In Late 2025

Dividend income has always been popular with stock market investors, especially older investors seeking yield. The recent correction in the technology-led market, and new forms of bond risk rising from President Trump's economic policy, may place even more focus on yield from dividend stocks.

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced new data from the OPTIMA II Phase 2b study of UGN‑102 (mitomycin) for intravesical solution demonstrate clinically meaningful two-year duration of response (24.2 months) by Kaplan-Meier analysis. UGN-102 is UroGen's sustained-release formulation of mitomycin being developed for the tre.

MarineMax reported resilient Q2 results, where sales surged in spite of a weak consumer environment. The company's cost savings caused earnings to also remain good. After Q2, the industry outlook has become worse. The consumer sentiment has declined further in April, causing slow sales. MarineMax cut its FY2025 guidance due to April weakness. MarineMax has significant debt. I still believe that the company should navigate the balance sheet well due to several factors.

SAN DIEGO, April 27, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of AppLovin Corporation (NASDAQ: APP) securities between May 10, 2023 and February 25, 2025, both dates inclusive (the “Class Period”), have until Monday, May 5, 2025 to seek appointment as lead plaintiff of the AppLovin class action lawsuit. Captioned Quiero v. AppLovin Corporation, Inc., No. 25-cv-02294 (N.D. Cal.), the AppLovin class action lawsuit charges AppLovin as well as certain of AppLovin's executives with violations of the Securities Exchange Act of 1934.

Zoldonrasib, a RAS(ON) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D mutant non-small cell lung cancer Zoldonrasib, a RAS(ON) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D mutant non-small cell lung cancer

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers and acquirers of Geron Corporation (NASDAQ: GERN) securities between February 28, 2024 and February 25, 2025. Geron is a commercial-stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Gero.

The technology sector has gotten off to a rough start this year. According to data from Yahoo!

Three sectors of the market have soared in recent years. However, there are laggards in each of them. I discuss why these underperformers are a golden buying opportunity for investors today.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, as a perioperative treatment regimen for patients with stage III or IVA, resected, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Results at the first interim analysis of the trial showed KEYTRUDA significantly improved event-free survival (EFS) as pa.

Tom Yeung here with your Sunday Digest. In the 1990s, my father moved our family to a new overseas “Florida-style” housing development.

Alphabet's Q1 2025 earnings were strong, showing Google is safe from AI disruption. However, I maintain a HOLD rating due to lack of diversification and potential recession risks. Valuation appears reasonable with a P/E of 17 vs. a historical median of 22.5, projecting a potential $220+ share price at a 21.5x forward P/E. I think Alphabet's revenue relies too much on advertising (~75%), with promising but limited diversification from Cloud (28% growth) and Subscriptions/Platforms (18% growth).

Financial markets grappled with a storm of political maneuvering around trade, taxes, and regulation, stoking some investor unease. During the recent period between index selection dates (March 13, 2025 – April 10, 2025, the “Period”), U.S. equity markets experienced severe volatility as escalating trade tensions drove a sharp repricing of risk assets.

Valley National Bancorp's stock is undervalued, trading below tangible book value, with a 14% total return potential including a 5% dividend yield. The bank has improved its capital and reserves, with a CET1 ratio of 10.8%, targeting over 11% by year-end. Valley's net interest margins are expected to improve as high-cost funding sources are replaced and the securities portfolio benefits from higher rates.

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of common stock of Fluence Energy, Inc. (NASDAQ: FLNC) between November 29, 2023 and February 10, 2025. Fluence describes itself as a company that “offers energy storage products and solutions, delivery services, recurring operational and maintenance services, and digital applications and solutions for energy storage and other power asse.